Patents by Inventor Alain Ravard

Alain Ravard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions for treating and/or preventing CNS disorders
    Patent number: 6624173
    Abstract: Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo [2.2.2]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: September 23, 2003
    Assignee: Targacept, Inc.
    Inventors: Peter Anthony Crooks, Gary Maurice Dull, William Scott Caldwell, Balwinder Singh Bhatti, Niranjan Madhukar Deo, Alain Ravard
  • Pharmaceutical compositions for prevention and treatment of central nervous system disorders
    Patent number: 5726316
    Abstract: Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-?3-(6-methylpyrindin)yl!-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: March 10, 1998
    Inventors: Peter Anthony Crooks, William Scott Caldwell, Gary Maurice Dull, Balwinder Singh Bhatti, Niranjan Madhukar Deo, Alain Ravard
  • Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
    Patent number: 5691365
    Abstract: Nicotine analogs that have nicotinic receptor antagonist properties. These compounds have been shown to competitively inhibit dopamine release induced by nicotine. The nicotine analog compounds are useful in the treatment of nicotine abuse, smoking cessation therapy, as an antidote for nicotine intoxication, treatment of cognitive disorders such as Alzheimer's disease and for the treatment of Parkinson's disease.
    Type: Grant
    Filed: July 18, 1995
    Date of Patent: November 25, 1997
    Assignee: University of Kentucky Research Foundation
    Inventors: Peter A. Crooks, Linda P. Dwoskin, Alain Ravard
  • Compounds which are useful for prevention and treatment of central nervous system disorders
    Patent number: 5616707
    Abstract: Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.
    Type: Grant
    Filed: January 6, 1995
    Date of Patent: April 1, 1997
    Inventors: Peter A. Crooks, William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Niranjan M. Deo, Alain Ravard